Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its Ccl24-Neutralizing Antibody Cm-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics宣佈新的出版物,加強其Cm-101中和Ccl24的抗體在原發性硬化性膽管炎中的臨床潛力。
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its Ccl24-Neutralizing Antibody Cm-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics宣佈新的出版物,加強其Cm-101中和Ccl24的抗體在原發性硬化性膽管炎中的臨床潛力。
譯文內容由第三人軟體翻譯。